volume 72, issue 12, P960-965 2014
DOI: 10.1590/0004-282x20140142
View full text
|
|
Share

Abstract: ABSTRACT Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated with increased risk of developing progressive multifocal leukoencephalopathy (PML). The evaluation of these conditions has been used to estimate risks of PML in these patients, and distinct (sometimes extreme) approaches are used to avoid the PML onset. A…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

2
11
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals